Literature DB >> 29732744

Early diagnosis of acute kidney injury in aged patients undergoing percutaneous coronary intervention.

Hong-Hua Ye1, Gen Shen1, Qun Luo2, Fang-Fang Zhou2, Xiao-Ling Xie1, Chun-Yan Wang1, Li-Na Han2.   

Abstract

In aged patients, acute kidney injury (AKI) is a common clinical complication after percutaneous coronary intervention (PCI), highlighting the need for timely and certain diagnosis of this disease. A single centre, nested case-control study was conducted, which assessed the usefulness of urinary liver-type fatty acid-binding protein (uL-FABP), neutrophil gelatinase-associated lipocalin (uNGAL), and kidney injury molecule-1 (uKIM-1) for early detection of AKI. One hundred and thirty-two patients at or over 60 years old undergoing PCI were included. Serum creatinine (SCr) was measured before PCI, 24 and 48 h after PCI; uL-FABP, uNGAL, and uKIM-1 were measured before PCI, 6, 24, and 48 h after PCI. We identified 16 AKI patients and selected 32 control patients matched by admission time (<1 week), age (±5 years), and gender. In the receiver operating characteristic (ROC) curve analysis, the areas under the curve (AUCs) for the relative measurements of uL-FABP, uNGAL, and uKIM-1 were 0.809, 0.867, and 0.512 at 6 h after PCI, and 0.888, 0.840, and 0.676 at 24 h after PCI, respectively. AUC for the combination of uL-FABP and uNGAL was 0.899 at 6 h after PCI, and 0.917 at 24 h after PCI. Thus, measurement of uL-FABP and uNGAL levels at 6 and 24 h after PCI may be useful in detecting AKI in aged patients. Measurement of uKIM-1 levels provides inferior predictive power for early diagnosis of AKI.

Entities:  

Keywords:  Liver-type fatty acid-binding protein; Neutrophil gelatinase-associated lipocalin; Kidney injury molecule-1; Percutaneous coronary intervention; Acute kidney injury

Mesh:

Substances:

Year:  2018        PMID: 29732744      PMCID: PMC5962510          DOI: 10.1631/jzus.B1700427

Source DB:  PubMed          Journal:  J Zhejiang Univ Sci B        ISSN: 1673-1581            Impact factor:   3.066


  21 in total

1.  Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium.

Authors:  Frank Dieterle; Frank Sistare; Federico Goodsaid; Marisa Papaluca; Josef S Ozer; Craig P Webb; William Baer; Anthony Senagore; Matthew J Schipper; Jacky Vonderscher; Stefan Sultana; David L Gerhold; Jonathan A Phillips; Gérard Maurer; Kevin Carl; David Laurie; Ernie Harpur; Manisha Sonee; Daniela Ennulat; Dan Holder; Dina Andrews-Cleavenger; Yi-Zhong Gu; Karol L Thompson; Peter L Goering; Jean-Marc Vidal; Eric Abadie; Romaldas Maciulaitis; David Jacobson-Kram; Albert F Defelice; Elizabeth A Hausner; Melanie Blank; Aliza Thompson; Patricia Harlow; Douglas Throckmorton; Shen Xiao; Nancy Xu; William Taylor; Spiros Vamvakas; Bruno Flamion; Beatriz Silva Lima; Peter Kasper; Markku Pasanen; Krishna Prasad; Sean Troth; Denise Bounous; Denise Robinson-Gravatt; Graham Betton; Myrtle A Davis; Jackie Akunda; James Eric McDuffie; Laura Suter; Leslie Obert; Magalie Guffroy; Mark Pinches; Supriya Jayadev; Eric A Blomme; Sven A Beushausen; Valérie G Barlow; Nathaniel Collins; Jeff Waring; David Honor; Sandra Snook; Jinhe Lee; Phil Rossi; Elizabeth Walker; William Mattes
Journal:  Nat Biotechnol       Date:  2010-05-10       Impact factor: 54.908

2.  Renal function-adjusted contrast volume redefines the baseline estimation of contrast-induced acute kidney injury risk in patients undergoing primary percutaneous coronary intervention.

Authors:  Giuseppe Andò; Cesare de Gregorio; Gaetano Morabito; Olimpia Trio; Francesco Saporito; Giuseppe Oreto
Journal:  Circ Cardiovasc Interv       Date:  2014-07-15       Impact factor: 6.546

3.  Urinary KIM-1, NGAL and L-FABP for the diagnosis of AKI in patients with acute coronary syndrome or heart failure undergoing coronary angiography.

Authors:  Isidro Torregrosa; Carmina Montoliu; Amparo Urios; María Jesús Andrés-Costa; Carla Giménez-Garzó; Isabel Juan; María Jesús Puchades; María Luisa Blasco; Arturo Carratalá; Rafael Sanjuán; Alfonso Miguel
Journal:  Heart Vessels       Date:  2014-07-03       Impact factor: 2.037

Review 4.  Biomarkers in acute kidney injury - pathophysiological basis and clinical performance.

Authors:  E V Schrezenmeier; J Barasch; K Budde; T Westhoff; K M Schmidt-Ott
Journal:  Acta Physiol (Oxf)       Date:  2016-08-25       Impact factor: 6.311

5.  Acute kidney injury after percutaneous coronary intervention: Rationale of the AKI-MATRIX (acute kidney injury-minimizing adverse hemorrhagic events by TRansradial access site and systemic implementation of angioX) sub-study.

Authors:  Giuseppe Andò; Bernardo Cortese; Enrico Frigoli; Andrea Gagnor; Stefano Garducci; Carlo Briguori; Paolo Rubartelli; Paolo Calabrò; Marco Valgimigli
Journal:  Catheter Cardiovasc Interv       Date:  2015-04-09       Impact factor: 2.692

Review 6.  Diagnostic value of neutrophil gelatinase-associated lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-analysis.

Authors:  Fangfang Zhou; Qun Luo; Lailiang Wang; Lina Han
Journal:  Eur J Cardiothorac Surg       Date:  2015-06-20       Impact factor: 4.191

Review 7.  Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis.

Authors:  Matthew T James; Susan M Samuel; Megan A Manning; Marcello Tonelli; William A Ghali; Peter Faris; Merril L Knudtson; Neesh Pannu; Brenda R Hemmelgarn
Journal:  Circ Cardiovasc Interv       Date:  2013-01-15       Impact factor: 6.546

8.  Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery.

Authors:  Chirag R Parikh; Heather Thiessen-Philbrook; Amit X Garg; Deepak Kadiyala; Michael G Shlipak; Jay L Koyner; Charles L Edelstein; Prasad Devarajan; Uptal D Patel; Michael Zappitelli; Catherine D Krawczeski; Cary S Passik; Steven G Coca
Journal:  Clin J Am Soc Nephrol       Date:  2013-04-18       Impact factor: 8.237

Review 9.  Neutrophil gelatinase-associated lipocalin: pathophysiology and clinical applications.

Authors:  E Singer; L Markó; N Paragas; J Barasch; D Dragun; D N Müller; K Budde; K M Schmidt-Ott
Journal:  Acta Physiol (Oxf)       Date:  2013-02-04       Impact factor: 6.311

Review 10.  Contrast-induced nephropathy and its prevention: What do we really know from evidence-based findings?

Authors:  Donald Reddan; Maurice Laville; Vesna D Garovic
Journal:  J Nephrol       Date:  2009 May-Jun       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.